Navigation Links
PTC Therapeutics Announces Additional $1.6 Million Grant from the Spinal Muscular Atrophy Foundation
Date:12/6/2007

Expanded Collaboration Focuses on Discovery of Small-Molecule Drugs for

Spinal Muscular Atrophy

SOUTH PLAINFIELD, N.J., Dec. 6 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, today announced an expanded research collaboration with the Spinal Muscular Atrophy (SMA) Foundation. The collaboration builds on the existing research agreement to identify and characterize compounds that have the potential to treat SMA by increasing production of the survival motor neuron (SMN) protein, the absence of which causes SMA. Under the terms of the expanded agreement, the SMA Foundation will provide an additional $1.6 million in funding to PTC based upon completion of certain milestones.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO )

"We are pleased to expand this collaboration with the SMA Foundation," stated Stuart W. Peltz, Ph.D., President and Chief Executive Officer of PTC Therapeutics. "By applying our proprietary technologies, we have made important progress in our efforts to identify treatments for SMA. This program is another example of the breadth of our approach and we look forward to our continued collaboration with the SMA Foundation as we seek to develop treatments for disorders with high unmet medical need."

"PTC has been an ideal partner in the identification of molecules targeting SMN," noted Meg Winberg, Director of Discovery Research for the SMA Foundation. "We have been impressed with their progress and are pleased to continue our work together to identify and advance potential treatments for SMA."

About Spinal Muscular Atrophy

Spinal muscular atrophy (SMA) is a genetic, motor neuron disease characterized by the wasting of skeletal muscles. Caused by progressive degeneration of nerve cells in the spinal cord, the disease leads to increasing muscular weakness and atrophy. It is estimated that approximately 1 in 6,000 to 1 in 10,000 infants are born annually worldwide with SMA. SMA is often compared to polio because the same spinal cord cells are attacked in each disease. Over time, patients afflicted by this disease continue to lose muscle control and strength, leading to progressive inability to walk, stand, sit up and breathe.

About the Spinal Muscular Atrophy Foundation

Founded in 2003, the Spinal Muscular Atrophy Foundation is a nonprofit organization dedicated to accelerating progress towards a treatment and cure for spinal muscular atrophy through targeted funding of clinical research and novel drug development efforts. Since its inception, the Foundation has awarded over $40 million in sponsored research agreements. In addition, the Foundation is committed to raising awareness and generating support for increased research efforts in SMA among the leaders of industry and government. For more information on the Spinal Muscular Atrophy Foundation, visit http://www.smafoundation.org or call (646) 253-7100.

About PTC Therapeutics, Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally-discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology and infectious diseases. In addition, PTC has developed proprietary technologies and extensive knowledge of post-transcriptional control processes that it applies in its drug discovery and development activities, including the Gene Expression Modulation by Small-molecules (GEMS) technology platform, which has been the basis for collaborations with leading pharmaceutical and biotechnology companies such as Pfizer, Celgene, CV Therapeutics and Schering- Plough.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
2. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
3. Prime Therapeutics Receives TIPPS Certification
4. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
5. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
6. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
7. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
8. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
9. Prime Therapeutics Announces URAC Accreditation
10. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
11. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... NC (PRWEB) , ... March 30, 2017 , ... ... will host the live audio conference “ Preventing Hospital Readmissions Through Discharge Planning ... 12, 2017 at 1:00 pm ET. This conference discusses strategies to prevent readmissions ...
(Date:3/29/2017)... ... 2017 , ... In the United States alone, up to 36% of primary ... of metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors are known ... effective treatment options, the San Diego Gamma Knife Center offers a precision-medicine ...
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER ... Mercy Medical Center will serve as the official title sponsor of the Baltimore Women’s ... 25, 2017, thousands of women will walk or run the course around the Baltimore ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy Network, a ... at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. , Ben ... the visionary leader in the training of physicians, scientists, and members of the ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with or without a ... compared to traditional orthodontic treatment. Depending on each patient’s case, treatment with the ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... TREE, Colo. , March 29, 2017  Zynex (OTCQB: ... manufacture and sale of non-invasive medical devices for pain ... today that it will host the Company,s 2016 full-year ... a.m. Eastern Time.) The Company expects to ... 31, 2017. ...
(Date:3/29/2017)... , March 29, 2017 According to a new ... Type (Gas-Filled Detectors, Geiger Muller, Survey Meter, Solid-State), Products (Personal Dosimeters, OSL, ... 2021" published by MarketsandMarkets, the market is expected to reach USD 1,215.4 ... of 6.5% from 2016 to 2021. Continue ... ...
(Date:3/29/2017)... , March 29, 2017  The Pharmaceutical Care ... a new PhRMA report on patient out-of-pocket spending: ... Medicare and Medicaid Services (CMS), the average amount spent ... 13% of drug spending in 2016, down from 23% ... a pricing problem, not a coverage problem. Health plans ...
Breaking Medicine Technology: